This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, E. A. Articles by Frank, J. L. Search for Related Content PubMed PubMed Citation Articles by Chen, E. A. Articles by Frank, J. L.

Routine Chest Roentgenography Is Unnecessary in the Work-Up of Stage I and II Breast Cancer

From the Departments of Surgery and Radiology, Baystate Medical Center, Springfield, MA.

Address reprint requests to James L. Frank, MD, Department of Surgery, Baystate Medical Center, Springfield, MA, 01199; email james.frank{at}bhs.org

PURPOSE: Clinical practice guidelines of many professional societies call for routine staging chest x-rays (SCXR) for all patients with invasive cancer. Given the estimated 157,000 patients annually for whom this recommendation pertains, this screening examination represents a considerable health care expenditure. If it were shown that SCXR rarely changed the management of low-risk subsets of this population, it might be possible to selectively omit this practice from the care of these patients with substantial resultant cost savings.

PATIENTS AND METHODS: All patients with clinical stage I and II breast cancer presenting to the Baystate Medical Center from 1989 through 1997 were identified through the Tumor Registry. Their hospital records were reviewed for clinical presentation and documentation of SCXR.

RESULTS: One thousand four hundred ninety-four patients were identified with clinical stage I and II disease. SCXR were available for review on 1,003 patients. Only one asymptomatic patient was upstaged to stage IV based on a SCXR. Two patients with primary lung tumors were also identified. These data demonstrate an asymptomatic pulmonary metastasis detection rate of 0.099% (95% confidence interval, 0.0% to 0.6%). The total charges of SCXR for this group approached $180,000.

CONCLUSION: These data demonstrate the low diagnostic yield and high cost of routine SCXR in the management of asymptomatic patients with clinical stage I and stage II breast cancer. Because other studies have shown that SCXR changes neither quality of life nor overall survival, SCXR should be limited to symptomatic patients in whom metastatic disease is suspected.

Presented at the annual meeting of the Society of Surgical Oncology, Orlando, FL, March 14, 1999.

This article has been cited by other articles:

				F. Puglisi, A. Follador, A. M. Minisini, G. G. Cardellino, S. Russo, C. Andreetta, S. Di Terlizzi, and A. Piga Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications Ann. Onc., February 1, 2005; 16(2): 263 - 266. [Abstract] [Full Text] [PDF]

				S. Tigges, D. L. Roberts, K. H. Vydareny, and D. A. Schulman Routine Chest Radiography in a Primary Care Setting Radiology, November 1, 2004; 233(2): 575 - 578. [Abstract] [Full Text] [PDF]

				A. Ravaioli, D. Tassinari, I. Panzini, C. Milandri, and D. Amadori Staging of Breast Cancer: It Is Time to Break With Tradition and Initiate the Evidence-Based-Medicine Age J. Clin. Oncol., February 15, 2001; 19(4): 1234 - 1234. [Full Text]